Sarepta Therapeutics, Inc. Stock Performance
as on November 21, 2025 at 2:29 am IST
Day's Low
Day's High
$16.31$17.6
1.03%
Downside
6.80%
Upside
52 Week's Low
52 Week's High
$10.42$138.8136.80%
Downside
742.29%
Upside
Sarepta Therapeutics, Inc. share price movements today
- Previous Close
- $16.39
- Open
- $16.53
- Volume
- 4.2M
- Day's Low - High
- $16.31 - $17.6
- 52 Week Low - High
- $10.42 - $138.81
Sarepta Therapeutics, Inc. Historical Returns
- 1 Month Return
- -28.89 %
- 3 Month Return
- -20.36 %
- 1 Year Return
- -85.22 %
- 3 Year Return
- -85.37 %
- 5 Year Return
- -87.51 %
Sarepta Therapeutics, Inc. Stock Fundamentals & Key Indicators
Check Sarepta Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.8B
EPS (TTM)
-2.067
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
26.64%
PE Ratio (TTM)
276.74
Industry PE ratio
19.200384615384614
PEG Ratio
159.25
EBITDA
-36.3M
Revenue (TTM)
2.4B
Profit Margin
-11.25%
Return On Equity TTM
-21.37%
Sarepta Therapeutics, Inc. Stock Valuation
Track how Sarepta Therapeutics, Inc. P/E has moved over time to understand its valuation trends.
Sarepta Therapeutics, Inc. in the last 5 years
Lowest (-94.84x)
March 31, 2025
Industry (19.20x)
November 20, 2025
Today (276.74x)
November 20, 2025
Highest (110.59x)
September 30, 2024
Today’s Price to Earnings Ratio: 276.74x
Sarepta Therapeutics, Inc. vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Sarepta Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.8B | -87.51% | 276.74 | -11.25% | |
| BUY | $43.4B | 421.01% | -16.34 | -264.83% | |
| BUY | $61.1B | 269.49% | 1651.07 | 1.36% | |
| BUY | $111.7B | 95.64% | 30.67 | 31.35% | |
| BUY | $76.9B | 35.47% | 17.39 | 32.13% |
Stock Returns calculator for Sarepta Therapeutics, Inc. Stock including INR - Dollar returns
The Sarepta Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Sarepta Therapeutics, Inc. investment value today
Current value as on today
₹20,036
Returns
Returns from Sarepta Therapeutics, Inc. Stock
Dollar Returns*
₹5,171 (+5.17%)
Analyst Recommendation on Sarepta Therapeutics, Inc. Stock
Based on 29 analysts
82.76%
Buy
17.24%
Hold
0.00%
Sell
Based on 29 analysts, 82.76% of analysts recommend a 'BUY' rating for Sarepta Therapeutics, Inc.. Average target price of $21.41
Sarepta Therapeutics, Inc. Share Price Target
Get share price movements and forecasts by analysts on Sarepta Therapeutics, Inc..
What analysts predicted
23.03%UPSIDE
Target Price
$21.41
Current Price
$16.48
Analyzed by
29 Analysts
Target
$21.41
Sarepta Therapeutics, Inc. target price $21.41, a slight upside of 23.03% compared to current price of $16.48. According to 29 analysts rating.
Sarepta Therapeutics, Inc. Stock’s Investor Sentiment and Interest
Investment in Sarepta Therapeutics, Inc. Shares on INDmoney has grown by 58.75% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:58.75% versus previous 30 day period
Search interest for Sarepta Therapeutics, Inc. Stock has increased by 175% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:175% versus previous 30 day period
Sarepta Therapeutics, Inc. Quarterly Profit & Loss
All numbers in Millions USD
Sarepta Therapeutics, Inc. Annual Profit & Loss
All numbers in Millions USD
Sarepta Therapeutics, Inc. Quarterly Cash Flow
All numbers in Millions USD
Sarepta Therapeutics, Inc. Annual Cash Flow
All numbers in Millions USD
Sarepta Therapeutics, Inc. News & Key Events
Today's Timeline - 14 November
Sat, 01:06 AM
-FDA approves new labeling for Elevidys, adding a Boxed Warning and restricting use to ambulatory patients aged four and older.
Insights on Sarepta Therapeutics, Inc.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
NO EFFECTAgainst Peers
In the last 3 years, Insmed Incorporated has given 975.3% return, outperforming this stock by 1060.5%
- NO EFFECT
Against Peers
In the last 1 year, Insmed Incorporated has given 175.8% return, outperforming this stock by 261.0%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 196.89M → -179.94M (in $), with an average decrease of 191.4% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, SRPT stock has moved down by -12.9%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 744.85M → 399.35M (in $), with an average decrease of 26.3% per quarter
About Sarepta Therapeutics, Inc.
| Organisation | Sarepta Therapeutics, Inc. |
| Headquarters | 215 First Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Mr. Douglas S. Ingram Esq., J.D. |
| E-voting on shares | Click here to vote |
Key Management of Sarepta Therapeutics, Inc.
Name | Title |
|---|---|
Mr. Douglas S. Ingram Esq., J.D. | CEO & Director |
Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations |
Ryan H. Wong | Executive VP & CFO |
Rachael Potter Ph.D. | Chief Scientific Officer |
Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer |
Mr. Ian Michael Estepan | President & COO |
Tamara Thornton | Director of Finance, Treasury & Investor Relations |
Ms. Cristin L. Rothfuss J.D. | Executive VP, Chief General Counsel & Corporate Secretary |
Ms. Alison Nasisi | Executive VP & Chief People Officer |
Patrick Moss Pharm.D. | Executive VP & Chief Commercial Officer |
FAQs
What is Sarepta Therapeutics, Inc. share price today?
Sarepta Therapeutics, Inc. share price today is $16.48 as on at the close of the market. Sarepta Therapeutics, Inc. share today touched a day high of $17.6 and a low of $16.31.
What is the 52 week high and 52 week low for Sarepta Therapeutics, Inc. share?
Sarepta Therapeutics, Inc. share touched a 52 week high of $138.81 on and a 52 week low of $10.42 on . Sarepta Therapeutics, Inc. stock price today i.e. is closed at $16.48,which is 88.13% down from its 52 week high and 58.23% up from its 52 week low.
What is Sarepta Therapeutics, Inc.'s market capitalisation today?
Sarepta Therapeutics, Inc. market capitalisation is $0.00T as on .
How to invest in Sarepta Therapeutics, Inc. Stock (SRPT) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Sarepta Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sarepta Therapeutics, Inc. Shares that will get you 0.0910 shares as per Sarepta Therapeutics, Inc. share price of $16.48 per share as on November 21, 2025 at 2:29 am IST.
What is the minimum amount required to buy Sarepta Therapeutics, Inc. Stock (SRPT) from India?
Indian investors can start investing in Sarepta Therapeutics, Inc. (SRPT) shares with as little as ₹88.68 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.80 in Sarepta Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Sarepta Therapeutics, Inc. share’s latest price of $16.48 as on November 21, 2025 at 2:29 am IST, you will get 0.6068 shares of Sarepta Therapeutics, Inc.. Learn more about
fractional shares .
What are the returns that Sarepta Therapeutics, Inc. has given to Indian investors in the last 5 years?
Sarepta Therapeutics, Inc. stock has given -87.51% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?